Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids

Hanbing Song, Simon Bucher, Katherine Rosenberg, Margaret Tsui, Deviana Burhan, Daniel Hoffman, Soo-Jin Cho, Arun Rangaswami, Marcus Breese, Stanley Leung, María V. Pons Ventura, E. Alejandro Sweet-Cordero, Franklin W. Huang (), Amar Nijagal () and Bruce Wang ()
Additional contact information
Hanbing Song: University of California, San Francisco
Simon Bucher: University of California, San Francisco
Katherine Rosenberg: University of California, San Francisco
Margaret Tsui: University of California, San Francisco
Deviana Burhan: University of California, San Francisco
Daniel Hoffman: University of California, San Francisco
Soo-Jin Cho: University of California, San Francisco
Arun Rangaswami: The Pediatric Liver Center at UCSF Benioff Childrens’ Hospitals
Marcus Breese: University of California, San Francisco
Stanley Leung: University of California, San Francisco
María V. Pons Ventura: University of California, San Francisco
E. Alejandro Sweet-Cordero: The Pediatric Liver Center at UCSF Benioff Childrens’ Hospitals
Franklin W. Huang: University of California, San Francisco
Amar Nijagal: University of California, San Francisco
Bruce Wang: University of California, San Francisco

Nature Communications, 2022, vol. 13, issue 1, 1-15

Abstract: Abstract Pediatric hepatoblastoma is the most common primary liver cancer in infants and children. Studies of hepatoblastoma that focus exclusively on tumor cells demonstrate sparse somatic mutations and a common cell of origin, the hepatoblast, across patients. In contrast to the homogeneity these studies would suggest, hepatoblastoma tumors have a high degree of heterogeneity that can portend poor prognosis. In this study, we use single-cell transcriptomic techniques to analyze resected human pediatric hepatoblastoma specimens, and identify five hepatoblastoma tumor signatures that may account for the tumor heterogeneity observed in this disease. Notably, patient-derived hepatoblastoma spheroid cultures predict differential responses to treatment based on the transcriptomic signature of each tumor, suggesting a path forward for precision oncology for these tumors. In this work, we define hepatoblastoma tumor heterogeneity with single-cell resolution and demonstrate that patient-derived spheroids can be used to evaluate responses to chemotherapy.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32473-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32473-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32473-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().